Prostate cancer other imaging findings: Difference between revisions
Jump to navigation
Jump to search
Shanshan Cen (talk | contribs) |
Farima Kahe (talk | contribs) |
||
| (14 intermediate revisions by 4 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{CMG}} | |||
{{CMG}} {{AE}} {{sali}} | |||
{{Prostate cancer}} | {{Prostate cancer}} | ||
==Overview== | ==Overview== | ||
[[ | [[Radionuclide]] may be helpful in the diagnosis of [[bone metastasis]] of prostate cancer. | ||
==Other Imaging Findings== | ==Other Imaging Findings== | ||
:* Test results suggest | *A [[Radionuclide]] uses bone-seeking radioactive materials ([[radiopharmaceuticals]]) and a computer to create a picture of the [[bones]]. It may be helpful in the diagnosis of bone metastasis of prostate cancer. <ref>Diagnosing prostate cancer.2015 Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/prostate/diagnosis/?region=ab#Bone_scan </ref> | ||
*Indications of using [[radionuclide]] imaging include: | |||
**Test results suggest an involvement of bone, such as increased [[alkaline phosphatase]] or [[calcium]] level | |||
**Unexplained [[bone pain]] in men | |||
===PET SCAN=== | |||
*[[PET scan]] has emerged as a promising staging modality for both primary and recurrent prostate cancer. | |||
*Newer tracers have increased detection accuracies for small, incipient metastatic foci. The clinical implications of these occult PET/CT detected disease foci require organized evaluation. | |||
*A classical positron emission tomography ([[PET scan]]) 18-F-fluorodeoxyglucose (FDG) is of limited utility in the management of prostate cancer, as the uptake of [[FDG]] in prostate cancer is highly variable. | |||
*Early studies suggest that 18-fluorine-labeled choline, 18-F sodium fluoride, fluciclovine F-18, and 11-carbon-labeled acetate may be better tracers for use in recurrent prostate cancer. Currently, the use of these tracers is considered investigational.<ref name="pmid29230009">{{cite journal |vauthors=Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF |title=The use of PET/CT in prostate cancer |journal=Prostate Cancer Prostatic Dis. |volume=21 |issue=1 |pages=4–21 |date=April 2018 |pmid=29230009 |doi=10.1038/s41391-017-0007-8 |url=}}</ref> | |||
[[File:Skeletal-metastases-1.jpg|300px|thumb|left|Showing bone metastasis of prostate cancer [https://radiopaedia.org/articles/prostate-cancer-3?lang=us source:Case courtesy of Dr Carlos Eduardo Anselmi, Radiopaedia.org, rID: 12294]]] | |||
<br style="clear:left" /> | |||
==References== | ==References== | ||
| Line 19: | Line 27: | ||
[[Category:Urology]] | [[Category:Urology]] | ||
[[Category:Types of cancer]] | [[Category:Types of cancer]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Urology]] | |||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
Latest revision as of 14:56, 14 January 2021
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Syed Musadiq Ali M.B.B.S.[2]
|
Prostate cancer Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Prostate cancer other imaging findings On the Web |
|
American Roentgen Ray Society Images of Prostate cancer other imaging findings |
|
Risk calculators and risk factors for Prostate cancer other imaging findings |
Overview
Radionuclide may be helpful in the diagnosis of bone metastasis of prostate cancer.
Other Imaging Findings
- A Radionuclide uses bone-seeking radioactive materials (radiopharmaceuticals) and a computer to create a picture of the bones. It may be helpful in the diagnosis of bone metastasis of prostate cancer. [1]
- Indications of using radionuclide imaging include:
- Test results suggest an involvement of bone, such as increased alkaline phosphatase or calcium level
- Unexplained bone pain in men
PET SCAN
- PET scan has emerged as a promising staging modality for both primary and recurrent prostate cancer.
- Newer tracers have increased detection accuracies for small, incipient metastatic foci. The clinical implications of these occult PET/CT detected disease foci require organized evaluation.
- A classical positron emission tomography (PET scan) 18-F-fluorodeoxyglucose (FDG) is of limited utility in the management of prostate cancer, as the uptake of FDG in prostate cancer is highly variable.
- Early studies suggest that 18-fluorine-labeled choline, 18-F sodium fluoride, fluciclovine F-18, and 11-carbon-labeled acetate may be better tracers for use in recurrent prostate cancer. Currently, the use of these tracers is considered investigational.[2]
References
- ↑ Diagnosing prostate cancer.2015 Canadian Cancer Society. http://www.cancer.ca/en/cancer-information/cancer-type/prostate/diagnosis/?region=ab#Bone_scan
- ↑ Li R, Ravizzini GC, Gorin MA, Maurer T, Eiber M, Cooperberg MR, Alemozzaffar M, Tollefson MK, Delacroix SE, Chapin BF (April 2018). "The use of PET/CT in prostate cancer". Prostate Cancer Prostatic Dis. 21 (1): 4–21. doi:10.1038/s41391-017-0007-8. PMID 29230009.